Berberine
Also sold as: Berberine hydrochloride · Berberine HCl · Dihydroberberine
A plant alkaloid studied mainly for glucose and lipid markers in metabolic disorders. It has meaningful interaction potential and cannot be equated with GLP-1 medicines or cardiovascular-outcome-proven treatment.
Longevity
Community
Not enough ratings yet: 0 of 10
Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.
Research
- Longevity: Metabolic-marker changes do not establish longer life or fewer cardiovascular events; no human longevity outcome is supplied.
REALITY CHECK // Short trials suggest improved glucose and lipid markers in metabolic disease, but many are small, heterogeneous and at risk of bias. Weight effects are modest, not evidence of GLP-1-drug equivalence, and enhanced absorption has not established better clinical outcomes.
Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.
Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.
Check your bottle
Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.
Enter the amount from your label to see the result.
How it was studied
01 // STUDIED_DOSE_RANGE
Human trial amounts
Standard berberine trials commonly used 500 mg two or three times daily (1000-1500 mg/day), usually for 8-24 weeks. These describe research exposure; they are not a prescription or an equivalent dose for DHB, phytosomes or micelles.
02 // TIMING_&_MATRIX
Trial schedules often divided
Research commonly used two or three daily HCl doses; food and splitting may affect GI tolerance but do not resolve drug interactions.
03 // EVALUATION_WINDOW
Usually 8-24 weeks
Most trials were short; outcome durability, long-term safety and cardiovascular-event prevention remain unresolved.
04 // SAFETY_&_QUALITY_GATE
Check context and label
No independently verified EFSA/NIH UL is supplied. The 1000-1500 mg/day trial range is not a safety ceiling. Long-term safety beyond 12 months and current regulatory thresholds remain insufficiently characterized in the dossier. Avoid during pregnancy, breastfeeding and infancy because of bilirubin-displacement concerns; avoid unsupervised use with jaundice/hyperbilirubinemia. Diabetes medicines, narrow-therapeutic-index drugs, immunosuppressants and liver disease require clinician/pharmacist review. Diarrhea, constipation, cramps and bloating occur; severe weakness, confusion, jaundice or palpitations need assessment. The dossier anecdotal liver-injury reports do not establish incidence or causation.
UPPER LIMIT // No independently verified EFSA/NIH UL is supplied. The 1000-1500 mg/day trial range is not a safety ceiling. Long-term safety beyond 12 months and current regulatory thresholds remain insufficiently characterized in the dossier.
Summary
Short trials suggest improved glucose and lipid markers in metabolic disease, but many are small, heterogeneous and at risk of bias. Weight effects are modest, not evidence of GLP-1-drug equivalence, and enhanced absorption has not established better clinical outcomes.
Mechanism
Mechanistic work implicates mitochondrial complex I/AMPK signaling, gut pathways and LDL-receptor regulation. Preclinical mechanisms and indirect GLP-1 secretion do not establish GLP-1 receptor agonism in humans.
Typical studied dose
Standard berberine trials commonly used 500 mg two or three times daily (1000-1500 mg/day), usually for 8-24 weeks. These describe research exposure; they are not a prescription or an equivalent dose for DHB, phytosomes or micelles.
Upper limit
No independently verified EFSA/NIH UL is supplied. The 1000-1500 mg/day trial range is not a safety ceiling. Long-term safety beyond 12 months and current regulatory thresholds remain insufficiently characterized in the dossier.
Popular stacks with Berberine
Not enough stack data yet. A combination with Berberine appears here once 5 people rate the same set.
Forms and label traps
| Form on label | Active content | Studied range / day | Absorption & GI tolerance | Verdict |
|---|---|---|---|---|
| Berberine HCl, stated salt mass Best for: Label comparison against the preparation actually studied. |
Extract weight · ~100% marker | 1000–1500 mg | Low oral exposure because of efflux and first-pass metabolism. Diarrhea, cramps, constipation and bloating are common dose-related limitations. |
Studied standard [REFERENCE // LABEL_BASIS] Compare standard HCl product mass to HCl-based trial exposure. 100% denotes the stated ingredient, not universal free-berberine equivalence across salts. |
| Dihydroberberine (DHB) Best for: Label comparison against the preparation actually studied. |
Unstandardized: active content unknown | no comparable trial range | Pilot human exposure data plus preclinical work; efficacy equivalence is unresolved. Tolerance depends on the amount and individual sensitivity. |
Caution [CAUTION // CHECK_FORM] Higher exposure in pilot pharmacokinetic work is not an established clinical-dose equivalence. No conversion factor or metabolic-outcome target is assigned. |
| Berberine phospholipid complex Best for: Label comparison against the preparation actually studied. |
Unstandardized: active content unknown | no comparable trial range | Formulation may raise exposure; clinical superiority is unproven. Tolerance depends on the amount and individual sensitivity. |
Caution [CAUTION // CHECK_FORM] Carrier mass is not pure berberine mass. Without a declared fraction and matched outcome trial, numerical substitution is not justified. |
| Micellar/nano berberine formulation Best for: Label comparison against the preparation actually studied. |
Unstandardized: active content unknown | no comparable trial range | Human formulation studies report altered exposure; some cited formulation work is animal-only. Tolerance depends on the amount and individual sensitivity. |
Caution [CAUTION // CHECK_FORM] Product-specific concentration and pharmacokinetics prevent a universal conversion. A short tolerability study does not establish long-term efficacy or safety. |
Common label traps
- TRAP_01 // Natural Ozempic gives equivalent weight loss
No credible head-to-head equivalence is supplied. Berberine is not an established GLP-1 receptor agonist; average weight effects are modest. - TRAP_02 // Natural means no interactions
Glucose lowering and CYP/transporter effects can matter clinically. Interaction strength depends on substrate, product and evidence; animal data cannot quantify human risk. - TRAP_03 // It replaces a statin or metformin
Short-term surrogate changes do not establish equivalent long-term outcomes or justify stopping prescribed treatment. - TRAP_04 // Higher blood exposure proves a superior supplement
DHB, micelle and phytosome pharmacokinetics do not establish superior metabolic outcomes, and can alter interaction risk.
Other outcomes studied
Outside the five leaderboard goals. Same evidence levels as above.
- TYPE 2 DIABETES MARKERS Moderate · benefit
Meta-analyses show a consistent direction for HbA1c, fasting/post-meal glucose and insulin-resistance markers, but many 8-24-week trials are small and at risk of bias. Early metformin comparisons do not establish interchangeable care.
PMID 34956436 PMID 38016844 PMID 25498346 PMID 18442638 PMID 19800084 PMID 39640489 - LIPIDS Moderate · benefit
Pooled trials report lower total/LDL cholesterol and triglycerides, with less consistent HDL changes. No cardiovascular-event equivalence to statins is established.
PMID 30466986 PMID 23512497 PMID 36313096 PMID 25498346 - PCOS Limited · benefit
Small heterogeneous trials suggest metabolic/endocrine effects; fertility/live-birth benefit is less certain and evidence may involve adjunctive treatment.
PMID 34407851 PMID 39236662 PMID 32811221 PMID 40269802 - BODY WEIGHT Limited · benefit
Meta-analyses suggest small changes in weight/BMI/waist; short heterogeneous studies do not justify GLP-1-equivalent claims.
PMID 41310257 PMID 32379652 PMID 32353823 - FATTY LIVER MARKERS Moderate · benefit
Pooled clinical work suggests liver-enzyme/steatosis marker improvements. Mixed clinical/preclinical reviews cannot establish hard liver outcomes, and the separate berberine-ursodeoxycholate drug is excluded.
PMID 38429794 PMID 40949129 PMID 38886838 PMID 38673787 - METABOLIC SYNDROME Moderate · benefit
A placebo-controlled-trial meta-analysis reports improvements across several metabolic markers. Surrogate improvement is not established mortality reduction.
PMID 40740996 PMID 40269802 - BLOOD PRESSURE Limited · benefit
Dedicated hypertension evidence is limited; this does not replace treatment or prove cardiovascular-event prevention.
PMID 33461163 PMID 25498346 - GLP-1 DRUG EQUIVALENCE No established evidence
Mechanistic reviews and preclinical AMPK work do not establish receptor-agonist action or semaglutide/tirzepatide-equivalent weight effects. No reliable head-to-head trial is supplied.
PMID 18285556 PMID 37921026 PMID 38957396
Reader questions
Is berberine a natural Ozempic?
No equivalent receptor pharmacology or clinical weight-loss efficacy is established. Modest metabolic effects do not justify substituting it for prescribed GLP-1 treatment.
Can I replace metformin or a statin?
No substitution can be inferred from short glucose/lipid trials. Discuss treatment goals and interactions with the prescriber.
Which formulation is best?
Standard HCl has the broader metabolic trial history. DHB/phytosome/micelle studies often measure exposure, so higher absorption does not establish better clinical results.
Can I take it while pregnant or breastfeeding?
Avoid it: the supplied dossier flags bilirubin-displacement risk in newborns and insufficient safety for pregnancy/lactation.
Why does it upset my gut?
A large fraction of standard oral berberine remains in the gut, and trials report diarrhea, constipation, cramps or bloating. Persistent or severe symptoms warrant clinical review rather than simply escalating the product.
Stack interactions
- Danger Diabetes medicines [DANGER // CLINICAL_REVIEW]
Potential additive glucose lowering needs clinical supervision. The human metformin PK study used goldenseal, a multi-alkaloid botanical, so its findings cannot be assigned wholesale to isolated berberine.
PMID 25498346 PMID 34956436 PMID 39943692 - Caution CYP3A/P-glycoprotein substrates [CAUTION // REVIEW_COMBINATION]
Reviews, animal experiments and models raise interaction concerns for selected statins, calcium-channel blockers and sedatives; they do not quantify a uniform human effect for every drug.
PMID 42653808 PMID 19370549 PMID 35048143 - Danger Cyclosporine and tacrolimus [DANGER // CLINICAL_REVIEW]
Narrow therapeutic margins warrant specialist review. The cyclosporine probe experiment cited used Coptidis Rhizoma in rats and cannot establish a uniform human inhibition direction.
PMID 29703381 PMID 34620272 PMID 42653808 - Caution Warfarin, digoxin and psychiatric medicines [CAUTION // REVIEW_COMBINATION]
CYP/transporter concerns motivate caution; direct strong clinical combination data are limited in the dossier.
PMID 42653808 - Caution Inositol, alpha-lipoic acid and other glucose-lowering products [CAUTION // REVIEW_COMBINATION]
Potential additive metabolic effects can complicate tolerability and glucose monitoring; supplement-stack outcome evidence is limited. - Caution Red yeast rice and absorption enhancers [CAUTION // REVIEW_COMBINATION]
Red yeast rice contains a statin-like monacolin; combining products can add muscle/liver or drug-exposure risks. Piperine/silymarin absorption claims are not a guarantee of safer efficacy.
Red flags: interactions and who should avoid it
Interactions
Diabetes medicines: Potential additive glucose lowering needs clinical supervision. The human metformin PK study used goldenseal, a multi-alkaloid botanical, so its findings cannot be assigned wholesale to isolated berberine. CYP3A/P-glycoprotein substrates: Reviews, animal experiments and models raise interaction concerns for selected statins, calcium-channel blockers and sedatives; they do not quantify a uniform human effect for every drug. Cyclosporine and tacrolimus: Narrow therapeutic margins warrant specialist review. The cyclosporine probe experiment cited used Coptidis Rhizoma in rats and cannot establish a uniform human inhibition direction. Warfarin, digoxin and psychiatric medicines: CYP/transporter concerns motivate caution; direct strong clinical combination data are limited in the dossier. Inositol, alpha-lipoic acid and other glucose-lowering products: Potential additive metabolic effects can complicate tolerability and glucose monitoring; supplement-stack outcome evidence is limited. Red yeast rice and absorption enhancers: Red yeast rice contains a statin-like monacolin; combining products can add muscle/liver or drug-exposure risks. Piperine/silymarin absorption claims are not a guarantee of safer efficacy.
Avoid or ask a doctor first if
Avoid during pregnancy, breastfeeding and infancy because of bilirubin-displacement concerns; avoid unsupervised use with jaundice/hyperbilirubinemia. Diabetes medicines, narrow-therapeutic-index drugs, immunosuppressants and liver disease require clinician/pharmacist review. Diarrhea, constipation, cramps and bloating occur; severe weakness, confusion, jaundice or palpitations need assessment. The dossier anecdotal liver-injury reports do not establish incidence or causation.
Sources (PubMed, 41)
- Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action.
PMID 18285556 · 2008 · Journal Article; Research Support; Non-U.S. Gov'tMechanistic reviews and preclinical AMPK work do not establish receptor-agonist action or semaglutide/tirzepatide-equivalent weight effects. No reliable head-to-head trial is supplied.
- Efficacy of berberine in patients with type 2 diabetes mellitus.
PMID 18442638 · 2008 · Journal Article; Randomized Controlled Trial; Research Support; N.I.H.; Extramural; Research Support; Non-U.S. Gov'tMeta-analyses show a consistent direction for HbA1c, fasting/post-meal glucose and insulin-resistance markers, but many 8-24-week trials are small and at risk of bias. Early metformin comparisons do not establish interchangeable care.
- Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp.
PMID 19370549 · 2009 · Journal ArticleDossier citation for preparation, pharmacokinetics or safety context; does not independently establish every efficacy or interaction claim on this card.
- Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression.
PMID 19800084 · 2010 · Comparative Study; Journal Article; Randomized Controlled Trial; Research Support; Non-U.S. Gov'tMeta-analyses show a consistent direction for HbA1c, fasting/post-meal glucose and insulin-resistance markers, but many 8-24-week trials are small and at risk of bias. Early metformin comparisons do not establish interchangeable care.
- 8,8-Dimethyldihydroberberine with improved bioavailability and oral efficacy on obese and diabetic mouse models.
PMID 20663675 · 2010 · Journal Article; Research Support; Non-U.S. Gov'tDossier citation for preparation, pharmacokinetics or safety context; does not independently establish every efficacy or interaction claim on this card.
- The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials.
PMID 23512497 · 2013 · Journal Article; Meta-Analysis; Research Support; Non-U.S. Gov't; Systematic ReviewPooled trials report lower total/LDL cholesterol and triglycerides, with less consistent HDL changes. No cardiovascular-event equivalence to statins is established.
- Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.
PMID 25498346 · 2015 · Journal Article; Meta-Analysis; Research Support; Non-U.S. Gov't; Systematic ReviewMeta-analyses show a consistent direction for HbA1c, fasting/post-meal glucose and insulin-resistance markers, but many 8-24-week trials are small and at risk of bias. Early metformin comparisons do not establish interchangeable care.
- Activation of P-glycoprotein and CYP 3A by Coptidis Rhizoma in vivo: Using cyclosporine as a probe substrate in rats.
PMID 29703381 · 2018 · Journal Article; Research Support; Non-U.S. Gov'tDossier citation for preparation, pharmacokinetics or safety context; does not independently establish every efficacy or interaction claim on this card.
- Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials.
PMID 30466986 · 2018 · Journal Article; Meta-Analysis; Systematic ReviewPooled trials report lower total/LDL cholesterol and triglycerides, with less consistent HDL changes. No cardiovascular-event equivalence to statins is established.
- The effect of Berberine on weight loss in order to prevent obesity: A systematic review.
PMID 32353823 · 2020 · Journal Article; Systematic ReviewMeta-analyses suggest small changes in weight/BMI/waist; short heterogeneous studies do not justify GLP-1-equivalent claims.
- The effect of berberine supplementation on obesity indices: A dose- response meta-analysis and systematic review of randomized controlled trials.
PMID 32379652 · 2020 · Journal Article; Meta-Analysis; Systematic ReviewMeta-analyses suggest small changes in weight/BMI/waist; short heterogeneous studies do not justify GLP-1-equivalent claims.
- The effect and safety of Berberine on polycystic ovary syndrome: a systematic review.
PMID 32811221 · 2021 · Journal Article; Systematic ReviewSmall heterogeneous trials suggest metabolic/endocrine effects; fertility/live-birth benefit is less certain and evidence may involve adjunctive treatment.
- Berberine for the treatment of hypertension: A systematic review.
PMID 33461163 · 2021 · Journal Article; Meta-Analysis; Systematic ReviewDedicated hypertension evidence is limited; this does not replace treatment or prove cardiovascular-event prevention.
- Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.
PMID 34407851 · 2021 · Journal Article; Network Meta-AnalysisSmall heterogeneous trials suggest metabolic/endocrine effects; fertility/live-birth benefit is less certain and evidence may involve adjunctive treatment.
- Tacrolimus and herbs interactions: a review.
PMID 34620272 · 2021 · Journal Article; ReviewDossier citation for preparation, pharmacokinetics or safety context; does not independently establish every efficacy or interaction claim on this card.
- Development of an Innovative Berberine Food-Grade Formulation with an Ameliorated Absorption: In Vitro Evidence Confirmed by Healthy Human Volunteers Pharmacokinetic Study.
PMID 34904017 · 2021 · Journal ArticleDossier citation for preparation, pharmacokinetics or safety context; does not independently establish every efficacy or interaction claim on this card.
- The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
PMID 34956436 · 2021 · Journal Article; Meta-Analysis; Systematic ReviewMeta-analyses show a consistent direction for HbA1c, fasting/post-meal glucose and insulin-resistance markers, but many 8-24-week trials are small and at risk of bias. Early metformin comparisons do not establish interchangeable care.
- Absorption Kinetics of Berberine and Dihydroberberine and Their Impact on Glycemia: A Randomized, Controlled, Crossover Pilot Trial.
PMID 35010998 · 2021 · Journal Article; Randomized Controlled TrialDossier citation for preparation, pharmacokinetics or safety context; does not independently establish every efficacy or interaction claim on this card.
- Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib.
PMID 35048143 · 2022 · Journal ArticleDossier citation for preparation, pharmacokinetics or safety context; does not independently establish every efficacy or interaction claim on this card.
- The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.
PMID 36313096 · 2022 · Systematic Review; Journal ArticlePooled trials report lower total/LDL cholesterol and triglycerides, with less consistent HDL changes. No cardiovascular-event equivalence to statins is established.
- Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: Part 1. Physicochemical and pharmacokinetic properties.
PMID 37057922 · 2023 · Journal Article; ReviewDossier citation for preparation, pharmacokinetics or safety context; does not independently establish every efficacy or interaction claim on this card.
- Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: part 2. development of oral dosage formulations.
PMID 37060323 · 2023 · Journal Article; ReviewDossier citation for preparation, pharmacokinetics or safety context; does not independently establish every efficacy or interaction claim on this card.
- Berberine-induced glucagon-like peptide-1 and its mechanism for controlling type 2 diabetes mellitus: a comprehensive pathway review.
PMID 37921026 · 2024 · Journal Article; ReviewMechanistic reviews and preclinical AMPK work do not establish receptor-agonist action or semaglutide/tirzepatide-equivalent weight effects. No reliable head-to-head trial is supplied.
- Characterization and Pharmacokinetic Assessment of a New Berberine Formulation with Enhanced Absorption In Vitro and in Human Volunteers.
PMID 38004546 · 2023 · Journal ArticleDossier citation for preparation, pharmacokinetics or safety context; does not independently establish every efficacy or interaction claim on this card.
- The Effect of Berberine Supplementation on Glycemic Control and Inflammatory Biomarkers in Metabolic Disorders: An Umbrella Meta-analysis of Randomized Controlled Trials.
PMID 38016844 · 2024 · Systematic Review; Journal ArticleMeta-analyses show a consistent direction for HbA1c, fasting/post-meal glucose and insulin-resistance markers, but many 8-24-week trials are small and at risk of bias. Early metformin comparisons do not establish interchangeable care.
- The clinical efficacy and safety of berberine in the treatment of non-alcoholic fatty liver disease: a meta-analysis and systematic review.
PMID 38429794 · 2024 · Journal Article; Meta-Analysis; Systematic Review; Research Support; Non-U.S. Gov'tPooled clinical work suggests liver-enzyme/steatosis marker improvements. Mixed clinical/preclinical reviews cannot establish hard liver outcomes, and the separate berberine-ursodeoxycholate drug is excluded.
- Berberine Effects in Pre-Fibrotic Stages of Non-Alcoholic Fatty Liver Disease-Clinical and Pre-Clinical Overview and Systematic Review of the Literature.
PMID 38673787 · 2024 · Journal Article; Systematic ReviewPooled clinical work suggests liver-enzyme/steatosis marker improvements. Mixed clinical/preclinical reviews cannot establish hard liver outcomes, and the separate berberine-ursodeoxycholate drug is excluded.
- Effects of different natural products in patients with non-alcoholic fatty liver disease-A network meta-analysis of randomized controlled trials.
PMID 38886838 · 2024 · Journal Article; Review; Network Meta-AnalysisPooled clinical work suggests liver-enzyme/steatosis marker improvements. Mixed clinical/preclinical reviews cannot establish hard liver outcomes, and the separate berberine-ursodeoxycholate drug is excluded.
- Research progress on pharmacological effects and bioavailability of berberine.
PMID 38888754 · 2024 · Journal Article; ReviewDossier citation for preparation, pharmacokinetics or safety context; does not independently establish every efficacy or interaction claim on this card.
- Molecular mechanisms, targets and clinical potential of berberine in regulating metabolism: a review focussing on databases and molecular docking studies.
PMID 38957396 · 2024 · Journal Article; ReviewMechanistic reviews and preclinical AMPK work do not establish receptor-agonist action or semaglutide/tirzepatide-equivalent weight effects. No reliable head-to-head trial is supplied.
- Berberine as adjuvant therapy for treating reduced fertility potential in women with polycystic ovary syndrome: A meta-analysis of randomized controlled trials.
PMID 39236662 · 2024 · Journal Article; Meta-Analysis; ReviewSmall heterogeneous trials suggest metabolic/endocrine effects; fertility/live-birth benefit is less certain and evidence may involve adjunctive treatment.
- Effects of administering berberine alone or in combination on type 2 diabetes mellitus: a systematic review and meta-analysis.
PMID 39640489 · 2024 · Journal Article; ReviewMeta-analyses show a consistent direction for HbA1c, fasting/post-meal glucose and insulin-resistance markers, but many 8-24-week trials are small and at risk of bias. Early metformin comparisons do not establish interchangeable care.
- The Pharmacokinetic Interaction Between Metformin and the Natural Product Goldenseal Is Metformin Dose-Dependent: A Three-Arm Crossover Study in Adults With Type 2 Diabetes.
PMID 39943692 · 2025 · Clinical Trial; Phase I; Journal Article; Randomized Controlled Trial; Research Support; N.I.H.; ExtramuralDossier citation for preparation, pharmacokinetics or safety context; does not independently establish every efficacy or interaction claim on this card.
- Berberine and health outcomes: an overview of systematic reviews.
PMID 40269802 · 2025 · Journal Article; Systematic ReviewSmall heterogeneous trials suggest metabolic/endocrine effects; fertility/live-birth benefit is less certain and evidence may involve adjunctive treatment.
- A 30-Day Randomized Crossover Human Study on the Safety and Tolerability of a New Micellar Berberine Formulation with Improved Bioavailability.
PMID 40278369 · 2025 · Journal ArticleDossier citation for preparation, pharmacokinetics or safety context; does not independently establish every efficacy or interaction claim on this card.
- Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials.
PMID 40740996 · 2025 · Journal Article; Systematic ReviewA placebo-controlled-trial meta-analysis reports improvements across several metabolic markers. Surrogate improvement is not established mortality reduction.
- Biochemical changes associated with non-alcoholic fatty liver disease in response to berberine treatment: a systematic review and meta-analysis of clinical and preclinical research.
PMID 40949129 · 2025 · Journal Article; Systematic ReviewPooled clinical work suggests liver-enzyme/steatosis marker improvements. Mixed clinical/preclinical reviews cannot establish hard liver outcomes, and the separate berberine-ursodeoxycholate drug is excluded.
- The effect of berberine on obesity indices: a systematic review and meta-analysis.
PMID 41310257 · 2026 · Journal Article; Meta-Analysis; Systematic ReviewMeta-analyses suggest small changes in weight/BMI/waist; short heterogeneous studies do not justify GLP-1-equivalent claims.
- Enhanced Apparent Oral Bioavailability of Berberine Through BioSOLVE Technology: Pharmacokinetic Evaluation of Metaberine™.
PMID 42367479 · 2026 · Journal ArticleDossier citation for preparation, pharmacokinetics or safety context; does not independently establish every efficacy or interaction claim on this card.
- Dihydroberberine in metabolic disorders: Bioavailability, molecular mechanisms, toxicology, and future perspectives.
PMID 42398618 · 2026 · Journal Article; ReviewDossier citation for preparation, pharmacokinetics or safety context; does not independently establish every efficacy or interaction claim on this card.
- Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review.
PMID 42653808 · 2026 · Journal Article; ReviewDossier citation for preparation, pharmacokinetics or safety context; does not independently establish every efficacy or interaction claim on this card.
Community comments
No approved comments yet. Comments are held for moderation.